ATP-binding cassette subfamily A member 5 suppresses pancreatic ductal adenocarcinoma progression and chemoresistance by promoting β-catenin ubiquitin-dependent degradation
Drug Resistance Updates · 2026
DOI: 10.1016/j.drup.2026.101381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Zhenchong Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Hui Ya Hospital of The First Affiliated Hospital, Sun Yat-sen University, Huizhou, Guangdong 516081, China; Guangdong …. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Drug Resistance, Neoplasm, ATP-Binding Cassette Transporters, beta Catenin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Basic and Applied Basic Research Foundation of Guangdong Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
AIMS: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies characterized by poor prognosis and resistance to therapy. Despite the most widely recognized role of ATP binding cassette (ABC) family transporters in multidrug resistance, emerging evidence suggests that ATP-binding cassette transporter A5 (ABCA5) acts as a tumor suppressor. Nevertheless, the role and molecular mechanism of ABCA5 in PDAC have not yet been fully investigated. METHODS: Using bulk and single-cell transcriptomics data and analysis of 80 clinical PDAC samples, we investigated the expression and clinical significance of ABCA5 in PDAC. In vitro and in vivo functional assays were conducted to explore the influence of ABCA5 on tumor growth, metastasis, and gemcitabine resistance. Immunofluorescence, mass spectrometry, co-immunoprecipitation, and ubiquitination assays were used to identify the direct interactions between factors. Patient-derived organoids (PDOs) were established to investigate the efficacy of ABCA5 overexpression in combination with gemcitabine and PRI-724 (a WNT inhibitor). RESULTS: Our study for the first time determined ABCA5 as a tumor suppressor in PDAC, and patients with low ABCA5 expression presented a poorer prognosis than those with high ABCA5 expression. Both in vitro and in vivo assays showed that overexpression of ABCA5 suppressed PDAC tumor growth, metastasis to the liver and lungs, as well as resistance to gemcitabine. In contrast, knockdown of ABCA5 had a tumor-promoting effect. Mechanistically, ABCA5 induced β-catenin ubiquitin-dependent degradation by binding to the WD40 repeat domain of BTRC (β-TrCP), a key E3 ubiquitin ligase, thereby inhibiting the WNT pathway. Importantly, PDOs revealed that overexpression of ABCA5 enhanced the treatment efficacy of gemcitabine, notably when combined with PRI-724. CONCLUSIONS: Collectively, our study demonstrates that ABCA5 is a potential therapeutic target for PDAC and provides a theoretical basis for a new combination therapy of ABCA5 regulation with gemcitabine and WNT inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Hui Ya Hospital of The First Affiliated Hospital, Sun Yat-sen University, Huizhou, Guangdong 516081, China; Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences),…
- Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China.
- Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, China.
- Maoming People's Hospital, Maoming, Guangdong 525000, China.
- Department of Andrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
- Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, Guangdong 300202, China.
Förderung
- China Postdoctoral Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Program key projects
Zitieren
APA
Li, Z., Ma, Z., Chen, Y., Yu, W., Yu, J., Lu, J., Zhang, Q., Wu, Q., Cai, Y., Wang, Z., Shang, C., Hou, B., Zhang, C., Huang, S., Wang, L., & Zhou, Q. (2026). ATP-binding cassette subfamily A member 5 suppresses pancreatic ductal adenocarcinoma progression and chemoresistance by promoting β-catenin ubiquitin-dependent degradation. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101381
Vancouver
Li Z, Ma Z, Chen Y, Yu W, Yu J, Lu J, et al. ATP-binding cassette subfamily A member 5 suppresses pancreatic ductal adenocarcinoma progression and chemoresistance by promoting β-catenin ubiquitin-dependent degradation. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101381
BibTeX
@article{Li2026,
author = {Li, Zhenchong and Ma, Zuyi and Chen, Yubin and Yu, Weixuan and Yu, Jiajie and Lu, Jianmin and Zhang, Qiaoling and Wu, Qianlong and Cai, Yifeng and Wang, Zeyao and Shang, Changzhen and Hou, Baohua and Zhang, Chuanzhao and Huang, Shanzhou and Wang, Linhe and Zhou, Qi},
title = {ATP-binding cassette subfamily A member 5 suppresses pancreatic ductal adenocarcinoma progression and chemoresistance by promoting β-catenin ubiquitin-dependent degradation},
journal = {Drug Resistance Updates},
year = {2026},
doi = {10.1016/j.drup.2026.101381}
}
EUVIMED